Lo A, Holmes K, Kamlapurkar S, et al. Multiomic characterization of oncogenic signaling mediated by wild-type and mutant RIT1. Sci Signal. 2021;14(711):eabc4520. doi:10.1126/scisignal.abc4520.
Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229-233. doi:10.1038/s41586-019-1668-3.
Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959-969. doi:10.1016/j.jhep.2018.01.009.
Yuan TL, Amzallag A, Bagni R, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018;22(7):1889-1902. doi:10.1016/j.celrep.2018.01.051.
Gilles M-E, Hao L, Huang L, et al. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018;24(7):1734-1747. doi:10.1158/1078-0432.CCR-17-2733.
Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018;6(3):282-300.e2. doi:10.1016/j.cels.2018.03.003.
Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005;102(17):5992-7. doi:10.1073/pnas.0502267102.
Bi WL, Greenwald NF, Ramkissoon SH, et al. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017;158(7):2284-2291. doi:10.1210/en.2016-1967.
Ryan RJH, Petrovic J, Rausch DM, et al. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017;21(3):784-797. doi:10.1016/j.celrep.2017.09.066.
Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645-651. doi:10.1038/s41588-018-0078-z.